Abstract
Introduction and Aims: We have investigated the accuracy of a serological marker to distinguish between septic and aseptic loosening of Total Hip Replacements (THR). We present the preliminary results of our ongoing prospective study.
Method: After obtaining Ethical Committee approval, 46 patients were collected in three groups: ‘control’ primary THR, revision THR for aseptic loosening and revision THR for infection. Serum IgG responses to an exocellular bacterial antigen (LipidS) were determined by enzyme-linked immunosorbent assay (ELISA).
Results: Our results show that the test can accurately differentiate between the patients with infected joint replacements and the control group. The test, to date, has a specificity of 93% and a sensitivity of 100%.
Conclusions: This simple and cheap test can reliably assist in the accurate evaluation of a painful hip arthroplasty, and planning for revision surgery. It will also be useful in the management of patients in whom the microbiology results are either negative or based on a single isolate of an organism, which may be either a contaminant or a possible pathogen. This, in turn, would have implications on financial costs and the optimum use of available resources.
These abstracts were prepared by Editorial Secretary, George Sikorski. Correspondence should be addressed to Australian Orthopaedic Association, Ground Floor, The William Bland Centre, 229 Macquarie Street, Sydney, NSW 2000, Australia.
At least one of the authors is receiving or has received material benefits or support from a commercial source.
